Rob Wright provides insight into the categories and shared attributes of superbosses, as derived from 10 years of research and more than 200 interviews by Sydney Finkelstein, #23 on the Thinker50 2017 rankings.

Sometimes it’s difficult to separate the identity of a company from that of its CEO. For example, when we think of Amazon and Microsoft we naturally think of Jeff Bezos and Bill Gates. In the biopharmaceutical industry, it is hard to ponder Alkermes without thinking of Richard Pops.

Thank goodness for the innovators in this industry that don’t fear failure. Because treatments for Alzheimer’s, cancers, and even headaches don’t (and won’t) come about just by wishing.

Rob Wright discusses the difference between collaboration and teamwork, and what companies and leaders should be focusing on.

How we can fix biopharma’s broken and battered image was the topic of a panel of seven biopharma executives convened this year by Life Science Leader at the JPM Conference in San Francisco.

The biopharmaceutical industry has made significant contributions toward providing better outcomes for numerous ailments but fixing the industry’s sagging image will require more than just developing drugs for dreaded diseases.

Deborah Waterhouse discusses her journey toward becoming CEO of ViiV Healthcare, an HIV joint venture between GSK, Pfizer and Shionogi, and her focus as a leader around innovation, building the “trust agenda” and company performance.

The Conference Forum’s invitation only R&D Leadership Summit sheds light on areas of focus and concern for top biopharmaceutical industry executives.

The story of how John Leonard found his “next adventure” in pharma as president and CEO of Intellia Therapeutics — and what he’s doing to capitalize on it.